Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status

Anni Sjöblom 1,*, Ulf-Håkan Stenman 2,†, Jaana Hagström 1,3,4,†, Lauri Jouhi 5, Caj Haglund 3,6, Stina Syrjänen 4,7, Petri Mattila 5, Antti Mäkitie 5,8,9,‡ and Timo Carpén 1,5,9,‡

Background: We studied the role of tumor-associated trypsin inhibitor (TATI) in serum with regard to HPV status in oropharyngeal squamous cell carcinoma (OPSCC) patients. Materials and methods: The study cohort included 90 OPSCC patients treated at the Helsinki University Hospital (HUS) in 2012–2016. TATI serum concentrations (S-TATIs) were determined by an immunofluorometric assay. Immunostaining was used to assess TATI tissue expression. HPV status was determined with a combination of p16 immunohistochemistry and HPV DNA PCR genotyping. The survival endpoints were overall survival (OS) and disease-specific survival (DSS). Results: A significant correlation was found between S-TATI positivity and poor OS (p = 0.01) and DSS (p = 0.04) in all patients. In HPV-negative cases, S-TATI positivity linked to poor OS (p = 0.01) and DSS (p = 0.05). In HPV-positive disease, S-TATI positivity correlated with poor DSS (p = 0.01). S-TATI positivity was strongly associated with HPV negativity. TATI serum was negatively linked to a lower cancer stage. TATI expression in peritumoral lymphocytes was associated with favorable OS (p < 0.025) and HPV positivity. TATI expression in tumor and in peritumoral lymphocytes correlated with lower cancer stages. Conclusion: Our results suggest that S-TATI positivity may be a biomarker of poor prognosis in both HPV-positive and HPV-negative OPSCC.

Simple Summary: Oropharyngeal squamous cell carcinoma (OPSCC) is a form of head and neck cancer in which human papillomavirus (HPV) infection has been shown to play a major role in disease development. The survival rates of HPV-positive patients are favorable compared to HPV-negative patients, but the reason for this phenomenon remains unclear. The management of OPSCC is complex, and development of novel treatment options is urgently required. Various possible factors affecting survival have been explored, including the tumor environment and cancer-related proteases. Our aim was to study a protease inhibitor known as tumor-associated trypsin inhibitor and its correlation with survival and clinical data in OPSCC patients.

Abstract: Background: We studied the role of tumor-associated trypsin inhibitor (TATI) in serum and in tumor tissues among human papillomavirus (HPV)-positive and HPV-negative OPSCC patients. Materials and methods: The study cohort included 90 OPSCC patients treated at the Helsinki University Hospital (HUS), Helsinki, Finland, in 2012–2016. TATI serum concentrations (S-TATIs) were determined by an immunofluorometric assay. Immunostaining was used to assess tissue expression. HPV status was determined with a combination of p16 immunohistochemistry and HPV DNA PCR genotyping. The survival endpoints were overall survival (OS) and disease-specific survival (DSS). Results: A significant correlation was found between S-TATI positivity and poor OS (p < 0.001) and DSS (p = 0.04) in all patients. In HPV-negative cases, S-TATI positivity was linked to poor OS (p = 0.01) and DSS (p = 0.05). In HPV-positive disease, S-TATI positivity correlated with poor DSS (p = 0.01). S-TATI positivity was strongly associated with HPV negativity. TATI serum was negatively linked to a lower cancer stage. TATI expression in peritumoral lymphocytes was associated with favorable OS (p < 0.025) and HPV positivity. TATI expression in tumor and in peritumoral lymphocytes correlated with lower cancer stages. Conclusion: Our results suggest that S-TATI positivity may be a biomarker of poor prognosis in both HPV-positive and HPV-negative OPSCC.
Keywords: OPSCC; HPV; TATI; survival

1. Introduction

The incidence of OPSCC has been increasing in recent years, particularly in Western countries [1]. Although over 100,000 new cases of oropharyngeal cancers are diagnosed yearly worldwide, the majority is diagnosed in developed countries [2,3]. Squamous cell carcinomas form over 90% of the newly diagnosed oropharyngeal cancers [2–6]. The median overall 5-year survival in Finland is 64% among men and 70% among women [7]. The most significant risk factors for OPSCC are smoking, heavy alcohol use, and HPV infection. Today, more than half of the new OPSCC cases are associated with HPV [8] and HPV-positive OPSCC and HPV-negative OPSCC are considered as separate disease entities. In HPV-positive OPSCC, the symptom profile and tumor characteristics differ from HPV-negative OPSCC, and the treatment response and the prognosis are usually substantially more favorable in HPV-related disease [9–11]. The prognosis for HPV-negative OPSCC remains relatively poor [12,13], and the explanation for poor survival rates remains unclear. To improve treatments and diagnostics, it is important to discover novel information on previously undiscovered prognostic factors and mechanisms affecting survival.

Various biomarkers have previously been associated with OPSCC, such as p16 [9,14,15]. Other potential biomarkers with possible prognostic value in OPSCC include Cyclin D1 and matrix metalloproteinases 1 and 2 [16–19]. Furthermore, recent studies have shown that HPV16 E6 and E7 serum antibody levels may predict OPSCC in advance [20,21]. However, to our knowledge there are currently no prognostic biomarkers or diagnostic serological biomarkers that are used for individualization of treatments for head and neck squamous cell cancers. Thus, further research on promising biomarkers is warranted. This study is focused on a biomarker known as tumor-associated trypsin inhibitor (TATI), which is associated with multiple malignancies, but has rarely been studied in oropharyngeal cancer [22,23].

TATI, also known as pancreatic secretory trypsin inhibitor (PSTI) or serine peptidase inhibitor Kazal type (SPINK1), is a trypsin inhibitor that functions mainly in the pancreas, where it serves as a suppressor of premature trypsinogen activation [24]. The mechanisms regulating extrapancreatic TATI secretion are only partially known. The reference range of TATI concentration in serum (S-TATI) is 3.2–16 µg/L in healthy individuals [25]. S-TATI has been shown to increase in several non-malignant conditions, such as acute pancreatitis and various other severe inflammatory diseases. Elevated secretion of TATI in cancer patients was first found in the urine of patients with ovarian cancer [26,27] and it has since been detected in serum and tumor tissue in various malignancies [25].

In addition to the role if TATI as a diagnostic tumor marker, it may have value as a prognostic marker [28], and as a target for cancer treatment [29]. The purpose of this study was to evaluate the significance of TATI as a biomarker in HPV-positive and HPV-negative OPSCC based on its expression in cancer tissue and its serum concentrations and to investigate its value as a prognostic factor.

2. Materials and Methods

2.1. Study Population

This study was based on an existing database used in previous studies [30,31] and it is consisted of a cohort of 224 patients with newly diagnosed oropharyngeal squamous cell carcinoma at the HUS, Helsinki, Finland in 2012–2016.

Inclusion criteria for this study were a prospectively collected serum sample analyzed for TATI concentration, and the previously determined HPV status in tissue samples. Altogether, 90 of the 224 patients fulfilled these criteria and were included in the final analysis.

Data were collected from electronic patient records and were updated during the study for assessment of prognosis. The data included clinical characteristics such as age, gender, smoking, use of alcohol, TNM class, stage, grade of differentiation, tumor localization,
HPV status using an algorithm described by Smeets et al. [32] As a treatment modality, patients received either (chemo)radiotherapy or surgery with or without post-operative (chemo)radiotherapy. All patients were treated with curative intent. The median follow-up time was 47.5 months (range 0.0–60.0). The survival endpoints were overall survival (OS) and disease-specific survival (DSS).

The study was approved by the Research Ethics Board at the HUS and an institutional permission for the study was granted (Dnr: 51/13/03/02/2013).

2.2. Tissue Microarrays

Tissue microarray (TMA) blocks were prepared from primary tumors with the assistance from digital software by Auria Biobank (Turku, Finland). Representative areas were selected from hematoxylin and eosin-stained slides and six 1-mm thick core biopsies from each tumor were detached from paraffin blocks. The cores were then placed in another block with a semiautomatic tissue microarrayer (Beecher Instruments, Silver Spring, MD, USA).

2.3. HPV Status Determination

In our study, HPV status was determined by Smeets’s algorithm using a combination of p16 immunohistochemistry (IHC) and HPV DNA detection.

All the paraffin-embedded samples were immunostained with p16-INK4a antibody. A positive control was included. HPV expression was considered as positive in samples where more than 70% of the tumor cells were positive.

For HPV DNA detection, DNA was first extracted from the tumor tissue samples followed by PCR-based genotyping using a Multiplex HPV Genotyping kit® (DiaMex GmbH, Heidelberg, Germany) as previously described [30]. Positivity of the high-risk (hr) HPV genotypes (subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66) in the samples was considered as a positive result for hrHPV DNA in the tumor.

The methodology of these procedures has been described in detail previously [30,31,33].

2.4. Determination of TATI Serum Concentrations

All serum samples (n = 90) were collected prior to treatment. S-TATI was determined by a time-resolved immunofluorometric assay (IFMA) using monoclonal antibodies (MAbs) produced in-house [34]. The capture antibody was coated onto microtitration wells and the detector antibody labeled with a europium chelate. TATI purified from the urine of a patient with ovarian cancer was used as a calibrator [27]. The calibrators covered the concentration range of 0.5–150 µg/L. The sample volume was 25 µg/L and the total assay volume was 200 µL. The detection limit of the assay was 0.15 µg/L and the CV < 10% was at concentrations in the range of 1–50 µg/L [34]. The reference range for S-TATI was 3.2–16 µg/L and it was determined based on the central 95% reference interval in a group of 152 apparently healthy subjects. The lower reference limit was 3.1 µg/L and the upper reference limit was 16 µg/L [34]. The upper reference limit was lower than that for the initially used radioimmunoassay (21 µg/L) [27]. This was attributed to the higher non-specific background of the RIA. Samples, where S-TATI exceeded the selected cut-off value 17 µg/L [24,25,35,36] were considered S-TATI positive.

2.5. IHC of TATI

IHC staining of TATI was analyzed in TMA slides. Deparaffinization and rehydration of the tissue slides was performed with Sakura Tissue-Tek DRS. The HIER method (heat induced epitope retrieval) was performed with the Pretreatment Module, Agilent Dako (Dako Denmark Aps, Glostrup, Denmark) to improve antigen retrieval in the samples. Endogenous peroxidase blocking was performed with EnVision Flex peroxidase-blocking reagent (Dako). A monoclonal TATI antibody (MAb 6E8) [37] was used as the primary antibody. Dako REAL Antibody Diluent S2022 (Dako) was used for antibody dilution. EnVision Flex/HRP SM802 DM827 (Dako) was used as a secondary antibody. The chromogen was EnVision Flex DAB (Dako). Hematoxylin was used for counterstaining. Staining was
performed with Autostainer 480 (Thermo Fisher Scientific, Vantaa, Finland). After the staining procedure, the specimen was dehydrated and then mounted with Pertex Histolab mounting media (Histolab Products Oy, Gothenburg, Sweden). We have not found evidence of non-specific staining while previously applying this method for TATI IHC and the specificity of the TATI antibody is described in earlier studies [34,36,37].

2.6. Sample Scoring

Scoring of TMA blocks was performed by two researchers (Anni Sjöblom and Jaana Hagström). A consensus was achieved in case of disagreements. TATI expression was assessed in the tumor tissue as well as in the peritumoral lymphocytes. The scoring of TATI in the samples was graded as described in Table S1.

2.7. Data Analysis

Data were collected and analyzed with IBM SPSS Statistics software program version 25. S-TATI and TATI expression in tumor tissues were compared with age, gender, smoking status, alcohol use, TNM class, stage, histological grade, tumor site and HPV status. Crosstab comparisons were performed with the \( \chi^2 \)-test and for normally distributed continuous variables, independent sample \( t \)-test was used. For the survival analysis, the selected endpoints were 5-year OS and DSS. OS was defined as the time from the last day of treatment to death from any cause. DSS was defined as the time from the last day of treatment to the date of OPSCC-related death. OS and DSS were assessed with the log-rank-test and illustrated with the Kaplan–Meier-estimator using GraphPad Prism-software version 9. For the univariable and multivariable analysis, the Cox regression analysis was performed. TATI serum concentrations were logarithmically transformed to obtain normal distribution. Variables receiving \( p \)-values under 0.05 in the univariable analysis were included to the multivariable analysis.

3. Results

3.1. TATI Serum Concentrations and Clinical Characteristics

S-TATI was determined in 90 serum samples. Based on a selected cut-off value of 17 \( \mu \text{g/L} \), 21 (23.3%) of the patients were considered TATI positive and 69 (76.7%) S-TATI negative. The crosstab comparisons of S-TATI according to clinical parameters are presented in Table 1.

The correlation between S-TATI and HPV status was statistically significant \( (p < 0.001) \). Most (90.60%) of the HPV-positive patients were S-TATI negative. Furthermore, S-TATI negativity was linked to lower cancer stage and higher histological grade (82.5% of the patients had cancer stages I-II and 83.3% of the patients were grade III). In addition, S-TATI negativity correlated with tonsil as tumor site (90.6% of the patients).

A majority (96.4%) of the non-smokers were S-TATI negative. Additionally, most (83.3%) of the former smokers were S-TATI negative. Among the smokers, 53.3% were S-TATI negative and 46.6% were S-TATI positive.

S-TATI positive patients had reduced OS during the 5-year follow-up and S-TATI positivity was linked to poor OS \( (p < 0.001) \) and DSS \( (p = 0.04) \) in the whole cohort. Furthermore, S-TATI positivity correlated with poor OS \( (p = 0.01) \) and DSS \( (p = 0.05) \) in HPV-negative patients and with poor DSS \( (p = 0.01) \) in HPV-positive patients. The survival curves according to S-TATI and OS are presented in Figure 1.

In the multivariate Cox regression analysis, poorer OS correlated significantly with age (adjusted Hazard ratio (HR) 1.08, 95% Confidence interval (CI) 0.03–1.13, \( p = 0.004 \)) and S-TATI (adjusted HR 2.47, 95% CI 1.26–4.84, \( p = 0.009 \)). In addition, poorer DSS was associated with age (adjusted HR 1.07, 95% CI 0.01–1.14, \( p = 0.018 \)) and S-TATI (adjusted HR 2.54, 95% CI 1.07–6.02, \( p = 0.034 \)) in the Cox regression multivariate model. The results of the multivariable analysis are presented in Table 2. In the multivariate Cox regression analysis with p16 as a separate variable, S-TATI correlated significantly with OS (adjusted
HR 2.49, 95% CI 1.28–4.83, \( p = 0.007 \) and DSS (adjusted HR 2.54, 95% CI 1.09–5.94, \( p = 0.031 \)) and the results are presented in Table S2.

**Table 1. Clinicopathological data according to S-TATI.**

| Variable          | S-TATI− % | S-TATI+ % | \( p \)-Value | Missing%/ (n = 90) |
|-------------------|-----------|-----------|---------------|-------------------|
| Number of patients| 69        | 21        | 0.054         |                   |
| Age               | 60.8      | 65.1      |               |                   |
| Gender            |           |           |               |                   |
| Male              | 52        | 14        | 21.2          |                   |
| Female            | 17        | 7         | 29.2          | 0.4               |
| Smoking           |           |           |               |                   |
| Never             | 27        | 1         | 3.6           |                   |
| Former            | 25        | 5         | 16.7          |                   |
| Current           | 17        | 15        | 46.9          | <0.001 **         |
| Heavy alcohol use |           |           |               | 16/17.8           |
| Never             | 36        | 7         | 16.3          |                   |
| Former            | 6         | 4         | 40.0          |                   |
| Current           | 13        | 8         | 38.1          | 0.09              |
| T class           |           |           |               |                   |
| T1-T2             | 46        | 12        | 13.3          |                   |
| T3-T4             | 23        | 9         | 10.0          | 0.4               |
| N class           |           |           |               |                   |
| N0–N1             | 59        | 15        | 20.3          |                   |
| N2–N3             | 10        | 6         | 37.4          | 0.2               |
| Stage             |           |           |               |                   |
| I–II              | 52        | 11        | 17.5          |                   |
| III–IV            | 17        | 10        | 37.0          | 0.04 *            |
| Grade             |           |           |               |                   |
| I                 | 1         | 2         | 66.7          |                   |
| II                | 8         | 7         | 46.7          |                   |
| III               | 60        | 12        | 16.7          | 0.009 *           |
| Localization      |           |           |               |                   |
| Tonsil            | 48        | 5         | 9.4           |                   |
| Base of tongue    | 17        | 5         | 22.7          |                   |
| Soft palate       | 3         | 7         | 70.0          |                   |
| Posterior wall of oropharynx | 1 | 4 | 80.0 | <0.001 ** |
| HPV               |           |           |               |                   |
| HPV−              | 21        | 16        | 43.2          |                   |
| HPV+              | 48        | 5         | 9.4           | <0.001 **         |

**Abbreviations:** TATI: Tumor-associated trypsin inhibitor; HPV: Human papillomavirus. \( p < 0.05 \), \( p < 0.001 \).

### 3.2. TATI Immunoexpression and Clinical Characteristics

Both serum and tissue data were available for 90 patients. For TATI IHC, adequate samples with HPV status determination were available for 77 (85.6%) patients. TATI was assessed in the tumor tissue in all 77 samples and in the tumor-adjacent lymphocytes in 76 samples (Figure 2a–c). Most of the samples showed moderate or strong IHC staining of TATI in both the tumor (63.3%) and in the peritumoral lymphocytes (60.5%). TATI-immunopositivity was cytoplasmic. TATI expression in IHC was associated with certain patient characteristics but not with S-TATI. Crosstab comparisons of TATI IHC and clinical characteristics are presented in Tables 3 and 4.
Table 2. Multivariate Cox regression analysis for overall-survival (OS) and disease-specific survival (DSS).

| Variable                        | OS    |                |       | DSS     |                |       |
|---------------------------------|-------|----------------|-------|---------|----------------|-------|
|                                 | HR    | 95% CI         | p-Value | HR      | 95% CI         | p-Value |
| Age                             | 1.08  | 1.03–1.13      | 0.004 * | 1.07    | 1.01–1.14      | 0.018 * |
| Smoking                         | 0.034 * | 0.205          |       |         |                |       |
| Ex-smoker versus never          | 1.20  | 0.27–5.40      | 0.816 | 0.62    | 0.10–3.98      | 0.615 |
| Current smoker versus never     | 4.14  | 1.22–14.06     | 0.023 * | 2.43    | 0.64–9.18      | 0.192 |
| Stage III–IV versus Stage I–II  | 1.71  | 0.70–4.20      | 0.243 | 2.19    | 0.72–6.64      | 0.168 |
| HPV-versus HPV+                 | 1.01  | 0.36–2.83      | 0.988 | 0.96    | 0.27–3.43      | 0.955 |
| S-TATI                          | 2.47  | 1.26–4.84      | 0.009 * | 2.54    | 1.07–6.02      | 0.034 * |

HR: Hazard ratio; CI: Confidence interval. S-TATI values are log-transformed. * p < 0.05.

Moderate or strong expression of TATI in tumor tissue and in peritumoral lymphocytes (Figure 2a,b) was observed in 83% and 69.8% of patients with stage I–II disease, respectively. Expression of TATI in tumor tissue did not significantly correlate with other clinical parameters. However, elevated expression of TATI in peritumoral lymphocytes was linked to HPV positivity (66.6%) and lower T class (71.4%). In addition, patients with moderate or strong expression of TATI in peritumoral lymphocytes had a favorable OS (p = 0.025). However, this result was only observed in the whole patient cohort and the comparisons between HPV status and survival was not statistically significant. No correlation was seen between DSS and TATI tissue expression.

![S-TATI and OS](Figure 1. Cont.)
Figure 1. (a) Overall survival (OS) according to positive (>17 μg/L) and negative (<17 μg/L) S-TATI in the whole patient cohort. (b) Overall survival (OS) according to positive and negative S-TATI in HPV-positive OPSCC patients. (c) Overall survival (OS) according to positive and negative S-TATI in HPV-negative OPSCC patients.
3.2. TATI Immunoexpression and Clinical Characteristics

Both serum and tissue data were available for 90 patients. For TATI IHC, adequate samples with HPV status determination were available for 77 (85.6%) patients. TATI was assessed in the tumor tissue in all 77 samples and in the tumor-adjacent lymphocytes in 76 samples (Figure 2a–c).

Most of the samples showed moderate or strong IHC staining of TATI in both the tumor (63.3%) and in the peritumoral lymphocytes (60.5%). TATI-immunopositivity was cytoplasmic. TATI expression in IHC was associated with certain patient characteristics but not with S-TATI. Crosstab comparisons of TATI IHC and clinical characteristics are presented in Tables 3 and 4.

Moderate or strong expression of TATI in tumor tissue and in peritumoral lymphocytes (Figure 2a,b) was observed in 83% and 69.8% of patients with stage I–II disease, respectively. Expression of TATI in tumor tissue did not significantly correlate with other clinical parameters. However, elevated expression of TATI in peritumoral lymphocytes was linked to HPV positivity (66.6%) and lower T class (71.4%). In addition, patients with moderate or strong expression of TATI in peritumoral lymphocytes had a favorable OS (p = 0.025). However, this result was only observed in the whole patient cohort and the comparisons between HPV status and survival was not statistically significant. No correlation was seen between DSS and TATI tissue expression.

Figure 2. (a) Moderate/strong TATI expression in tumor tissue. (b) Moderate/strong TATI expression in peritumoral lymphocytes and mild expression in the tumor tissue. (c) Negative TATI expression in the tumor tissue. Scale bar length 50 μm. Magnification ×200.

| Variable          | TATI in Tumor 0–1 | %   | TATI in Tumor 2–3 | %   | p-Value | Missing/% (n = 77) |
|-------------------|-------------------|-----|-------------------|-----|---------|-------------------|
| Number of patients| 20                | 26.0| 57                | 63.3|         |                   |
| Age               | 64.4              | 61.1|                   |     |         |                   |
| Gender            |                   |     |                   |     |         |                   |
| Male              | 15                | 25.4| 44                | 74.6|         |                   |
| Female            | 5                 | 27.8| 13                | 72.2| 0.8     |                   |
| Smoking           |                   |     |                   |     |         |                   |
| Never             | 8                 | 33.3| 16                | 66.7|         |                   |
| Former            | 7                 | 28.0| 18                | 72.0|         |                   |
| Current           | 5                 | 17.9| 23                | 82.1| 0.4     |                   |
| Heavy alcohol use |                   |     |                   |     |         |                   |
| Never             | 14                | 35.9| 25                | 64.1|         |                   |
| Former            | 1                 | 16.7| 5                 | 83.3|         |                   |
| Current           | 4                 | 22.2| 14                | 77.8| 0.4     |                   |
| T class           |                   |     |                   |     |         |                   |
| T1–T2             | 11                | 22.4| 38                | 77.6|         |                   |
| T3–T4             | 9                 | 32.1| 19                | 67.9| 0.4     |                   |
| N class           |                   |     |                   |     |         |                   |
| N0–N1             | 12                | 19.0| 51                | 81.0|         |                   |
| N2–N3             | 8                 | 57.1| 6                 | 42.9| 0.006 * |                   |
Table 3. Cont.

| Variable            | TATI in Tumor 0–1 % | TATI in Tumor 2–3 % | p-Value | Missing/% (n = 77) |
|---------------------|---------------------|---------------------|---------|-------------------|
| **Stage**           |                     |                     |         |                   |
| I–II                | 9                   | 17.0                | 44      | 83.0              |
| III–IV              | 11                  | 45.8                | 13      | 54.1              | 0.007 * |
| **Grade**           |                     |                     |         |                   |
| I                   | 0                   | 0.0                 | 2       | 100.0             |
| II                  | 3                   | 23.0                | 10      | 77.0              |
| III                 | 17                  | 27.4                | 45      | 72.6              | 0.7    |
| **Localization**    |                     |                     |         |                   |
| Tonsil              | 10                  | 21.7                | 36      | 78.3              |
| Base of tongue      | 6                   | 35.3                | 11      | 64.7              |
| Soft palate         | 3                   | 33.3                | 6       | 66.7              |
| Posterior wall of oropharynx | 1        | 20.0                | 4       | 80.0              | 0.7    |
| **HPV**             |                     |                     |         |                   |
| HPV−                | 9                   | 29.0                | 22      | 71.0              |
| HPV+                | 11                  | 23.9                | 35      | 76.1              | 0.6    |

Abbreviations: TATI: tumor-associated trypsin inhibitor; HPV: Human papillomavirus, TATI immunoexpression was scored in the tumor tissue, TATI in tumor 0–1: mild positivity, TATI in tumor 2–3: moderate-strong positivity, p < 0.05 *.

Table 4. Clinicopathological data according to TATI expression in tumor-adjacent lymphocytes.

| Variable            | TATI in Lymphocytes 0–1 % | TATI in Lymphocytes 2–3 % | p-Value | Missing/% (n = 76) |
|---------------------|---------------------------|---------------------------|---------|-------------------|
| **Number of patients** | 30                        | 39.5                      | 46      | 60.5              |
| **Age**             | 62.6                      | 61.3                      |         | 0.6               |
| **Gender**          |                           |                           |         |                   |
| Male                | 23                        | 39.7                      | 35      | 60.3              |
| Female              | 7                         | 38.9                      | 11      | 61.1              | 0.9    |
| **Smoking**         |                           |                           |         |                   |
| Never               | 10                        | 43.5                      | 13      | 56.5              |
| Former              | 5                         | 20.0                      | 20      | 80.0              |
| Current             | 15                        | 53.6                      | 13      | 46.4              | 0.04 * |
| **Heavy alcohol use** |                          |                           |         |                   |
| Never               | 17                        | 44.7                      | 21      | 55.3              |
| Former              | 1                         | 16.7                      | 5       | 83.3              |
| Current             | 9                         | 50.0                      | 9       | 50.0              | 0.4    |
| **T Class**         |                           |                           |         |                   |
| T1–T2               | 14                        | 28.6                      | 35      | 71.4              |
| T3–T4               | 16                        | 59.3                      | 11      | 40.7              | 0.009 * |
| **N Class**         |                           |                           |         |                   |
| N0–N1               | 23                        | 36.5                      | 40      | 63.5              |
| N2–N3               | 7                         | 53.8                      | 6       | 46.2              | 0.2    |
| **Stage**           |                           |                           |         |                   |
| I–II                | 16                        | 30.2                      | 37      | 69.8              |
| III–IV              | 14                        | 60.9                      | 9       | 39.1              | 0.01 * |
| **Grade**           |                           |                           |         |                   |
| I                   | 1                         | 50.0                      | 1       | 50.0              |
| II                  | 6                         | 46.2                      | 7       | 53.8              |
| III                 | 23                        | 37.7                      | 38      | 62.3              | 0.8    |
| **Localization**    |                           |                           |         |                   |
| Tonsil              | 15                        | 32.6                      | 31      | 67.4              |
| Base of tongue      | 6                         | 37.5                      | 10      | 62.5              |
| Soft palate         | 6                         | 66.7                      | 3       | 33.3              |
| Posterior wall of oropharynx | 3        | 60.0                      | 2       | 40.0              | 0.2    |
| **HPV**             |                           |                           |         |                   |
| HPV−                | 18                        | 60.0                      | 12      | 40.0              |
| HPV+                | 12                        | 33.3                      | 34      | 66.6              | 0.003 * |

Abbreviations: TATI: Tumor-associated trypsin inhibitor; HPV: Human papillomavirus, TATI immunoexpression was scored in the inflammatory cells adjacent to the tumor tissue, TATI in lymphocytes 0–1: mild positivity, TATI in lymphocytes 2–3: moderate-strong positivity, p < 0.05 *.
4. Discussion

Our study revealed novel information on TATI in both serum and in tumor tissue among OPSCC patients. Our findings suggest that S-TATI positivity is linked with poor prognosis of OPSCC irrespective of HPV status. In recurrent HPV-negative disease managed with primary definitive oncological treatment, the prognosis is usually considerably impaired. Therefore, determining the S-TATI could provide an advantage for the patient when establishing the treatment plan. Additionally, S-TATI determination could be valuable in monitoring purposes during posttreatment follow-up. In earlier studies TATI was shown to have prognostic value in other cancers [35,38]. Considering our results, further research with larger cohorts assessing TATI as a prognostic biomarker in OPSCC is warranted.

To the best of our knowledge, there are no studies on TATI in OPSCC. Interestingly, we found that S-TATI was associated with survival in both HPV-negative and HPV-positive disease, particularly in HPV-negative OPSCC. Given the limitations of the small sample size, we were not able to thoroughly analyze the effect of HPV status on S-TATI levels. As S-TATI positivity was associated with HPV negativity, it is likely that the association between poor prognosis and S-TATI positivity in the whole OPSCC group is strongly related to concurrent HPV negativity. Interestingly, we found a correlation between S-TATI positivity and poor DSS in HPV-positive patients. According to these findings, S-TATI positivity may have individual effects on survival unrelated to HPV negativity, although our sample size in this analysis was small. Studies on larger cohorts are needed to determine the role of HPV status and S-TATI for prognostication purposes. However, we observed that elevated S-TATI appears to function as an independent prognostic biomarker in OPSCC (Table 2). Similar results were observed in other malignancies [28,39,40].

In our study, previous and present smoking correlated strongly with S-TATI positivity (\( p < 0.001 \)). Interestingly, similar results were observed in a previous study [41]. Furthermore, evidence of possibly smoking-related mutations in TATI has been found in chronic pancreatitis [42]. We speculate that smoking could increase mutations in TATI, possibly impairing its functions and thus leading to poor prognosis, TATI upregulation in serum, or both. Further research is required to establish the connection between smoking and TATI upregulation in OPSCC.

The mechanisms regulating TATI secretion in cancer are not known. Thus, the cause of the elevated TATI levels in serum and tissue in OPSCC and other malignancies is unclear. In general, it appears that TATI may have different effects on prognosis and pathogenesis depending on the type of malignancy [24]. There are several theories concerning the regulation of TATI in cancer and one of most frequently encountered is the connection of TATI with the protease tumor-associated trypsin (TAT) [43–45]. TAT and TATI are often produced simultaneously, and TAT has previously been linked to several malignancies and pathological conditions [46]. We speculate that TATI is acting through TAT, which is known to activate other proteinases mediating tissue destruction and invasion [43,47]. Low tissue expression of TATI could increase TAT activity due to the lack of inhibition. This phenomenon may facilitate local tumor invasion, which is associated with poor prognosis. This theory would support our findings of S-TATI positivity signaling impaired survival but does not align with our IHC results. Overexpression of TAT along with low TATI expression has previously been associated with enhanced tumor-cell invasion in oral and gastric cancer [47]. These results conflict with our findings regarding S-TATI positivity linked with poor prognosis. This contradiction might reflect the fact that their study was done in vitro with cell lines and is not directly comparable with our clinical study.

Recent studies on other malignancies have provided compelling theories on TATI and its effects on cancer aggressiveness and survival. The importance of the tumor microenvironment and the tumorigenic abilities of stromal cells is associated with prognosis [29,45]. The senescence-associated secretory phenotype (SASP), a known feature of cellular senescence, is associated with cancer and stromal cells [48]. It has been suggested that SASP in stromal cells is a mediator of paracrine S-TATI upregulation and of various cancer-
promoting mechanisms (such as invasiveness), and it is associated with poor prognosis in prostate cancer [29]. Although SASP was observed after chemoradiation by Chen et al., similar events might stimulate S-TATI expression in OPSCC. Furthermore, SASP has previously been shown to trigger various cancer-promoting features with different mechanisms in oral squamous cell carcinomas [49]. Therefore, we speculate that SASP may be an important contributor to S-TATI upregulation in OPSCC and these events may also lead to poor prognosis as well. Our findings of S-TATI positivity being linked to poor prognosis support this theory. These explanations do not completely align with our IHC results.

Although we did not observe any correlation between S-TATI and TATI expression in tumor tissues, there was a moderate correlation between S-TATI negativity and tissue positivity. Interestingly, it has not been possible to establish an association between elevated S-TATI and tumor tissue in previous studies [28,50]. It has been speculated that TATI protects tissues against cancer invasion [43]. This would be consistent with our observations of TATI positivity of tumor-adjacent lymphocytes and several favorable associated factors, i.e., lower T class and stage. We speculate that while TATI expression is mainly increased in tumors and their surrounding tissues, TATI protein possibly locates in the tissues, which might reduce secretion into the blood. According to our results both negative S-TATI and high TATI expression in the peritumoral lymphocytes were linked to lower disease stage.

Several previous studies have failed to show elevated S-TATI and TATI expression in tumor tissues as associated prognostic factors [43,44,50]. Our findings indicate a significant association between poor prognosis and S-TATI positivity and these results appear to be more distinct compared to the IHC results. Further research is required to establish correlation between TATI expression in tissues and S-TATI as prognostic factors in cancer.

The present results could provide a novel path for future OPSCC research. To the best of our knowledge, there are no other serum biomarker assays for diagnostic and monitoring purposes of oral and oropharyngeal cancers.

5. Conclusions

Based on the present results, serum TATI appears to be a promising prognostic biomarker in HPV-positive and HPV-negative OPSCC. Prospective studies and further research in larger cohorts are warranted to determine the functions and physiology of TATI in OPSCC more thoroughly.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13112811/s1; Table S1: TATI immunoscoring, Table S2: Multivariate Cox regression analysis for overall-survival (OS) and disease-specific survival (DSS) with p16 as a separate variable.

Author Contributions: Conceptualization, U.-H.S., T.C. and L.J.; methodology, A.S., T.C., L.J., J.H., S.S. and U.-H.S.; software, T.C. and L.J.; validation, T.C., L.J., J.H., U.-H.S., A.M. and C.H.; formal analysis, T.C. and L.J.; investigation, A.S.; resources, data curation, A.S.; writing—original draft preparation, A.S.; writing—review and editing, A.S., T.C., L.J., J.H., U.-H.S., A.M., C.H., S.S. and P.M.; visualization, J.H. and A.S.; supervision, T.C., J.H. and A.M.; project administration T.C., J.H. and A.M., funding acquisition, A.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Helsinki University Hospital Research Fund and the Sigrid Juselius Foundation.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of HUS (Dnr: 51/13/03/02/2013).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to patient data security.

Acknowledgments: Open access funding provided by University of Helsinki including Helsinki University Hospital. The authors thank Pia Saarinen (HUS) for technical assistance.
Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| HIER         | Heat-induced epitope retrieval |
| HPV          | Human papillomavirus |
| HUS          | Helsinki University Hospital |
| IFMA         | Immunofluorometric assay |
| Mab          | Monoclonal antibody |
| OPSCC        | Oropharyngeal squamous cell carcinoma |
| OS           | Overall survival |
| SASSP        | Senescence-associated secretory phenotype |
| S-TATI       | Serum concentration of tumor-associated trypsin inhibitor |
| TAT          | Tumor-associated trypsin |
| TATI         | Tumor-associated trypsin inhibitor |
| TMA          | Tissue microarray |

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018, GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 2018, 68, 394–424. [CrossRef] [PubMed]

2. Warnakulasuriya, S. Global epidemiology of oral and oropharyngeal cancer. *Oral Oncol.* 2009, 45, 309–316. [CrossRef] [PubMed]

3. Lambert, R.; Sauvaget, C.; de Camargo Cancela, M.; Sankaranarayanan, R. Epidemiology of cancer from the oral cavity and oropharynx. *Eur. J. Gastroenterol. Hepatol.* 2011, 23, 633–641. [CrossRef] [PubMed]

4. Sinevici, N.; O’Sullivan, J. Oral cancer: Deregulated molecular events and their use as biomarkers. *Oral Oncol.* 2016, 61, 12–18. [CrossRef] [PubMed]

5. Koneva, L.A.; Zhang, Y.; Virani, S.; Hall, P.B.; McHugh, J.B.; Chepeha, D.B.; Wolf, G.T.; Carey, T.E.; Rozek, L.S.; Sartor, M.A. HPV integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. *Mol. Cancer Res.* 2018, 16, 90–102. [CrossRef] [PubMed]

6. Gooi, Z.; Chan, J.Y.K.; Fakhry, C. The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. *Laryngoscope* 2016, 126, 894–900. [CrossRef]

7. Pitkäniemi, J.; Malila, N.; Virtanen, A.; Degerlund, H.; Heikkinen, S.; Seppä, K. *Syöpä 2018. Tilastoraportti Suomen Syöpätilanteesta*, Publication no. 93 of Cancer Society of Finland; Cancer Society of Finland: Helsinki, Finland, 2020. Available online: [https://www.epressi.com/media/userfiles/145405/1588150481/syopa-2018-pa-finska.pdf](https://www.epressi.com/media/userfiles/145405/1588150481/syopa-2018-pa-finska.pdf) (accessed on 3 June 2021).

8. Chaturvedi, A.K.; Anderson, W.F.; Lortet-Tieulent, J.; Curado, M.P.; Ferlay, J.; Rosenberg, P.S.; Bray, F.; Gillison, M.L. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J. Clin. Oncol.* 2013, 31, 4550–4559. [CrossRef]

9. Gillison, M.L.; D’Souza, G.; Westra, W.; Sugar, E.; Xiao, W.; Begum, S.; Viscidi, L. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. *J. Natl. Cancer Inst.* 2008, 100, 407–420. [CrossRef] [PubMed]

10. Rameqvi, T.; Dalianis, T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. *Anticancer Res.* 2011, 31, 1515–1519. [PubMed]

11. Ang, K.K.; Harris, J.; Wheeler, R.; Weber, R.; Rosenthal, D.I.; Nguyen-Tân, P.F.; Westra, W.H.; Chung, C.H.; Jordan, R.C.; Lu, C.; et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N. Engl. J. Med.* 2010, 363, 24–35. [CrossRef] [PubMed]

12. Fakhry, C.; Westra, W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J. Natl. Cancer Inst.* 2008, 100, 261–269. [CrossRef] [PubMed]

13. Elrefaey, S.; Massaro, M.A.; Chiocca, S.; Chiesa, F.; Ansarin, M. HPV in oropharyngeal cancer: The basics to know in clinical practice. *Acta Otorhinolaryngol. Ital.* 2014, 34, 299–309.

14. Sato, F.; Ono, T.; Kawahara, A.; Kawaguchi, T.; Tanaka, H.; Shimamatsu, K.; Kakuma, T.; Akiba, J.; Umeno, H.; Yano, H. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. *J. Clin. Pathol.* 2019, 72, 542–549. [CrossRef] [PubMed]

15. Adelstein, D.J.; Ismaila, N.; Ku, J.A.; Burtness, B.; Swiecicki, P.L.; Mell, L.; Beitel, J.J.; Gross, N.; Jones, C.U.; Kaufman, M.; et al. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. *J. Clin. Oncol.* 2019, 37, 1578–1589. [CrossRef] [PubMed]

16. Grimminger, C.M.; Danenberg, P.V. Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: A review. *Eur. Arch. Otorhinolaryngol.* 2011, 268, 5–16. [CrossRef] [PubMed]

17. Vento, S.I.; Jouhi, L.; Mohamed, H.; Haglund, C.; Mäkitie, A.A.; Atula, T.; Hagström, J.; Mäkinen, L.K. MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma. *Virchows Arch.* 2018, 472, 975–981. [CrossRef] [PubMed]

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| HIER         | Heat-induced epitope retrieval |
| HPV          | Human papillomavirus |
| HUS          | Helsinki University Hospital |
| IFMA         | Immunofluorometric assay |
| Mab          | Monoclonal antibody |
| OPSCC        | Oropharyngeal squamous cell carcinoma |
| OS           | Overall survival |
| SASSP        | Senescence-associated secretory phenotype |
| S-TATI       | Serum concentration of tumor-associated trypsin inhibitor |
| TAT          | Tumor-associated trypsin |
| TATI         | Tumor-associated trypsin inhibitor |
| TMA          | Tissue microarray |

References
18. Umbreit, C.; Erben, P.; Faber, A.; Hofheinz, R.-D.; Aderhold, C.; Weiss, C.; Hoermann, K.; Wenzel, A.; Schultz, J.D. MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. *Anticancer Res.* 2015, 35, 3801–3810.

19. Plath, M.; Broglie, M.A.; Fürbs, D.; Stoeckli, S.J.; Jochum, W. Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma. *J. Otolaryngol. Head Neck Surg.* 2018, 47, 53. [CrossRef]

20. Lang Kuhs, K.A.; Wood, C.B.; Wigginton, J.; Aulinö, J.M.; Latimer, B.; Smith, D.K.; Bender, N.; Rohde, S.; Mannion, K.; Kim, Y.; et al. Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer. *Cancer* 2020, 126, 2658–2665. [CrossRef]

21. Ren, J.; Xu, W.; Su, J.; Ren, X.; Cheng, D.; Chen, Z.; Bender, N.; Mirshams, M.; Habbous, S.; De Almeida, J.R.; et al. Multiple imputation and clinic-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. *Int. J. Cancer* 2020, 146, 2166–2174. [CrossRef] [PubMed]

22. Rivera, C.; Oliveira, A.K.; Costa, R.A.P.; De Rossi, T.; Paes Leme, A.F. Prognostic biomarkers in oral squamous cell carcinoma: A systematic review. *Oral Oncol.* 2017, 72, 38–47. [CrossRef] [PubMed]

23. Almangush, A.; Heikkinen, I.; Mäkitie, A.A.; Coletta, R.D.; Läärä, E.; Leivo, I.; Salo, T. Prognostic biomarkers for oral tongue squamous cell carcinoma: A systematic review and meta-analysis. *Br. J. Cancer* 2017, 117, 856–866. [CrossRef] [PubMed]

24. Itkonen, O.; Stenman, U.-H. TATI as a biomarker. *Clin. Chim. Acta* 2014, 431, 260–269. [CrossRef]

25. Räsänen, K.; Itkonen, O.; Koistinen, H.; Stenman, U.-H. Emerging Roles of SPINK1 in Cancer. *Clin. Chem.* 2016, 62, 449–457. [CrossRef]

26. Eddeland, A.; Ohlsson, K. A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids. *Hoppe Seyler Z. Physiol. Chem.* 1978, 359, 671–675. [CrossRef]

27. Stenman, U.H.; Huhtala, M.L.; Koistinen, R.; Seppälä, M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. *Int. J. Cancer* 1982, 30, 53–57. [CrossRef]

28. Gaber, A.; Nordin, B.; Hotakainen, K.; Nilsson, E.; Stenman, U.-H.; Bjartell, A.; Birgisson, H.; Jirström, K. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. *BMC Cancer* 2010, 10, 498. [CrossRef] [PubMed]

29. Chen, F.; Long, Q.; Fu, D.; Zhu, D.; Ji, Y.; Han, L.; Zhang, B.; Xu, Q.; Liu, B.; Li, Y.; et al. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. *Nat. Commun.* 2018, 9, 4315. [CrossRef] [PubMed]

30. Randén-Brady, T.; Carpén, T.; Jouhi, L.; Syrjänen, S.; Haglund, C.; Tarkkanen, J.; Remes, S.; Mäkitie, A.; Mattila, P.S.; Siilén, S.; et al. In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer. *Hum. Pathol.* 2019, 90, 97–105. [CrossRef] [PubMed]

31. Carpén, T.; Syrjänen, S.; Jouhi, L.; Randén-Brady, R.; Haglund, C.; Mäkitie, A.; Mattila, P.S.; Hagström, J. Epstein-Barr virus (EBV) and polyomaviruses are detectable in oropharyngeal cancer and EBV may have prognostic impact. *Cancer Immunol. Immunother.* 2020, 69, 1615–1626. [CrossRef] [PubMed]

32. Smeets, S.J.; Hesselink, A.T.; Speel, E.-J.M.; Haesevoets, A.; Snijders, P.J.F.; Pawlita, M.; Meijel, C.J.L.M.; Braakhuis, B.J.M.; Leemans, C.; Brakenhoff, R.H. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. *Int. J. Cancer* 2009, 125, 2465–2472. [CrossRef] [PubMed]

33. Osman, S.; Turpeinen, U.; Itkonen, O.; Stenman, U.-H. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. *J. Immunol. Methods* 1993, 161, 91–96. [CrossRef]

34. Lyytinen, I.; Lempinen, M.; Nordin, A.; Mäkisalo, H.; Stenman, U.-H.; Isoniemi, H. Prognostic significance of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. *Clin. Chim. Acta* 2018, 373, 106–107. [CrossRef]

35. Ravela, S.; Valmu, L.; Domanskyy, M.; Koistinen, H.; Kylanpaa, L.; Lindstrom, O.; Stenman, U.-H.; Itkonen, S.; et al. An immunocapture-LC-MS-based assay for serum SPINK1 allows simultaneous quantification and detection of SPINK1 variants. *Anal. Bioanal. Chem.* 2017, 409, 1679–1688. [CrossRef]

36. Paju, A.; Hotakainen, K.; Cao, Y.; Laurila, T.; Gadaleanu, V.; Hemminki, A.; Stenman, U.H.; Bjartell, A. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. *Eur. Urol.* 2007, 52, 1670–1679. [CrossRef]

37. Kelloniemi, I.; Rintala, E.; Einn, P.; Stenman, U.-H. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. *Urology* 2003, 62, 249–253. [CrossRef]

38. Tornberg, S.V.; Nisen, H.; Järvinen, P.; Järvinen, R.; Kihlmar, T.P.; Taari, K.; Stenman, U.H.; Visapää, H. Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. *Scand. J. Urol.* 2020, 54, 110–118. [CrossRef]

39. Kozakiewicz, B.; Chadzyńska, M.; Dmoch-Gajzlerska, E.; Stefaniak, M. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. *Tumor Biol.* 2016, 37, 9367–9374. [CrossRef] [PubMed]

40. Järvisalo, J.; Hakama, M.; Leino, A.; Teppo, L.; Maatale, J.; Aromaa, A. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. *Cancer* 1993, 71, 1982–1988. [CrossRef]
42. Zou, W.-B.; Tang, X.-Y.; Zhou, D.-Z.; Qian, Y.-Y.; Hu, L.-H.; Yu, F.-F.; Yu, D.; Wu, H.; Deng, S.-J.; Lin, J.-H. SPINK1, PRSS1, CTRC, and CFTR Genotypes Influence Disease Onset and Clinical Outcomes in Chronic Pancreatitis. *Clin. Transl. Gastroenterol.* 2018, 9, 204. [CrossRef]

43. Gaber, A.; Johansson, M.; Stenman, U.-H.; Hotakainen, K.; Pontén, F.; Glimelius, B.; Jirström, B.K.; Birgisson, H. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. *Br. J. Cancer* 2009, 100, 1540–1548. [CrossRef]

44. Wiksten, J.-P.; Lundin, J.; Nordling, S.; Kokkola, A.; Stenman, U.-H.; Haglund, C. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. *Histopathology* 2005, 46, 380–388. [CrossRef]

45. Tiwari, R.; Manzar, N.; Bhatia, V.; Yadav, A.; Nengroo, M.A.; Datta, D.; Carskadon, S.; Gupta, N.; Sigouros, M.; Khani, F.; et al. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. *Nat. Commun.* 2020, 11, 384. [CrossRef] [PubMed]

46. Soreide, K.; Janssen, E.A.; Körner, H.; Baak, J.P.A. Trypsin in colorectal cancer: Molecular biological mechanisms of proliferation, invasion, and metastasis. *J. Pathol.* 2006, 209, 147–156. [CrossRef]

47. Nyberg, P.; Moilanen, M.; Paju, A.; Sarin, A.; Stenman, U.-H.; Sorsa, T.; Salo, T. MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. *J. Dent. Res.* 2002, 81, 831–835. [CrossRef]

48. Kuilman, T.; Michaloglou, C.; Mooi, W.J.; Peeper, D.S. The essence of senescence. *Genes Dev.* 2010, 24, 2463–2479. [CrossRef] [PubMed]

49. Prime, S.S.; Cirillo, N.; Hassona, Y.; Lambert, D.W.; Paterson, I.C.; Mellone, M.; Thomas, G.J.; James, E.N.L.; Parkinson, E.K. Fibroblast activation and senescence in oral cancer. *J. Oral Pathol. Med.* 2017, 46, 82–88. [CrossRef]

50. Lukkonen, A.; Lintula, S.; von Boguslawski, K.; Carpén, O.; Ljungberg, B.; Landberg, G.; Stenman, U.H. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. *Int. J. Cancer* 1999, 83, 486–490. [CrossRef]